Montana Authorizes Open Market for Unproven Drugs and Longevity Therapies
Montana has finalized regulations allowing biotech firms to sell experimental treatments to any consenting adult, bypassing traditional FDA terminal illness restrictions. The state-sanctioned program enables companies to set their own prices for unapproved drugs after a private review process.
Key takeaways
- Montana now allows any consenting adult to buy experimental drugs, moving beyond previous restrictions that limited access to the terminally ill.
- Biotech companies can set their own prices for unapproved treatments, with potentially no upper limit on costs for patients.
- A private five-member review board must approve applications, though the FDA has not issued assurances to participating firms.
- The legislation was heavily influenced by longevity advocates seeking to fast-track preventative and anti-aging therapies outside federal channels.
A New Frontier for Experimental Medicine
Montana has formally transitioned into a unique testing ground for the biotech industry. Following the finalization of rules by the state’s Department of Health and Human Services on July 25, 2025, any adult resident can now legally purchase drugs that have not received federal approval. Unlike traditional national and state 'right-to-try' statutes, which limit access to the terminally ill, Montana’s framework extends to anyone providing informed consent. This includes those seeking treatments for rare conditions as well as individuals pursuing unproven longevity and preventative therapies.
The Private Review Infrastructure
Under the new state guidelines, biotech firms wanting to bypass the standard FDA trajectory must navigate a specific local protocol. Companies with drugs that have completed preliminary safety testing—sometimes involving as few as ten healthy subjects—can apply for access for a fee of $12,500. Evaluation is handled by an Experimental Treatment Review Board (ETRB). This panel must consist of five members, including a Montana-certified physician, scientific experts, and an ethicist.
The first such panel, the Montana ETRB, was recently launched by Montana Governance Services Inc. While it currently operates as the sole reviewer in the state, organizers clarify it is a private entity rather than a government body. Board member Matt Kaeberlein asserts the process will maintain rigorous oversight through medical professionals, despite the absence of federal involvement.
Economic Risks and Regulatory Uncertainty
The program introduces significant financial and legal variables for both patients and manufacturers. Key distinctions between Montana's law and federal expanded-access programs include:
- Unrestricted Pricing: There are no state-imposed caps on what companies can charge, meaning experimental cycles could cost hundreds of thousands of dollars.
- Liability and FDA Standing: Some biotech firms remain wary. The FDA has not provided formal assurances that participating in Montana’s program will not jeopardize future federal drug applications or regulatory standing.
- Longevity Focus: The legislation was heavily influenced by groups like the Alliance for Longevity Initiatives (A4LI) and tech entrepreneur Niklas Anzinger, focusing on life extension rather than just terminal care.
State Senator Ken Bogner, who championed the 2023 expansion of the law, noted the objective was to shift toward preventative medicine. The first experimental treatment clinics are expected to begin operations by the end of this year, marking a significant departure from established American pharmaceutical regulation.
Source: MIT Technology Review
Related stories
Google AI Surge Triggers Historic Spike in Chrome Security Vulnerability Fixes
